腹腔镜下腹腔灌洗引流对重症急性胰腺炎全身炎症反应的影响

目的:探讨腹腔镜下置管腹腔灌洗引流(LPLD)对重症急性胰腺炎(SAP)全身炎症反应的影响.方法:37例SAP患者按入院先后顺序随机分为内科组和LPLD组.检测并比较两组治疗前后0、1、3、7、10 d外周血内毒素、TNF-α、IL-lβ、IL-6的浓度及单核细胞NF-κB的活性.结果:第0天 LPLD组内毒素、TNF-α、IL-lβ、IL-6浓度及单核细胞NF-κB活性与内科组比较无显著差异;术后第10天,LPLD组内毒素、TNF-α、IL-lβ、IL-6浓度及单核细胞NF-κB活性分别为(1.64±0.13)pg/mL、(114.13±15.12)pg/mL、(80.17±18.06)pg/mL、(56.43±12.24)pg/mL、(68.2±1.7)%.上述指标与内科组比较均有显著下降(P<0.01 or P<0.05).结论:LPLD能明显减轻内毒素血症,减低NF-κB活性及细胞因子浓度,有效地减轻SAP患者的炎症反应.     

肠内免疫微生态营养支持对肝切除患者肝功能的影响

目的探讨肠内营养（EN）和肠内免疫微生态营养（EIN）对肝切除术后患者肝脏功能的影响。方法将82例肝切除患者随机分为两组,手术后分别接受肠内营养和肠内免疫微生态营养1周,观察两种营养方式对患者内毒素、细胞因子及肝功能的影响。结果术前EIN组内毒素、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）及肝功能与EN组比较差异无统计学意义（P〉0．05）。营养支持1周后,EIN组内毒素、TNF-α和IL-6分别为（1．88±0．17）pg／ml、（260±28）pg／ml、（158±8）pg／ml,上述指标均较EN组明显下降（P〈0．01或P〈0．05）。EIN组1周后肝功能各项指标与EN组比较差异有统计学意义（P〈0．01或P〈0．05）。结论肠内免疫微生态营养,可以补充肠道正常菌群,减少细菌易位,减少内毒素血症及炎症因子的发生,从而减轻肝切除术后的肝损害。     

依达拉奉对肝脏缺血再灌注损伤保护作用的临床研究

目的观察依达拉奉对肝切除术患者肝缺血再灌注损伤的保护作用。方法82例肝切除患者,随机分为对照组（n=40）和试验组（n=42）,试验组给予依达拉奉。分别于术前及术后测定中性粒细胞（PMN）计数、血清谷丙转氨酶（ALT）、谷草转氨酶（AST）含量及肝组织中丙二醛（MDA）及超氧化物岐化酶（SOD）活件。结果肝脏缺血再灌注损伤后,对照组的ALT、AST水平及MDA含量明显高于试验组（P〈0．01或P〈0．05）,SOD活性及PMN计数明显下降（P〈0．05）。结论依达拉奉对肝脏的缺血再灌注损伤有显著的保护作用,其机制可能与减少PMN在肝脏内的聚集进而调节肝组织氧化与抗氧化平衡有关。     

高渗盐水对重症急性胰腺炎患者血流动力学及血清炎症因子水平的影响

目的 观察高渗盐水对重症急性胰腺炎(SAP)患者的血流动力学及血清炎症因子水平的影响,为临床应用高渗盐水治疗SAP提供理论依据.方法 57例SAP患者完全随机分为对照组(28例)和高渗盐水组(29例).高渗盐水组患者入院后每天按4 ml/kg输入7.5％高渗盐水,对照组患者则在相同时段输入0.9％氯化钠溶液,余治疗相同.分别于入院时及治疗后1、3、7、14 d记录患者平均动脉压(MAP)、HR、中心静脉压(CVP)的变化;酶联免疫吸附法动态检测血清中肿瘤坏死因子α、白细胞介素10浓度,动态比浊法测定血清内毒素含量.结果 治疗后第1天和第7天,高渗盐水组MAP、CVP明显高于对照组[(130±48)mm Hg(1 mm Hg=0.133 kPa)比(104±43)mm Hg,( 129±36) mm Hg比(104±31) mm Hg;(8.39±2.91)cm H2O(1 cm H2O =0.098 kPa)比(5.92±2.84) cm H2O,(8.82±2.69) cm H2O比(6.41±3.10) cmH2O,P＜0.05],而治疗后第3天,高渗盐水组HR明显高于对照组[(98±19)次/min比(126±27)次/min,P＜0.05];治疗后第14天,高渗盐水组内毒素、肿瘤坏死因子-α、白细胞介素-10水平明显低于对照组[(2.70±0.13) ng/L比(3.25±0.30) ng/L,( 30.13±8.12) ng/L比(313.42±144.35) ng/L,( 586.45±14.54) ng/L比(412.72±48.55) ng/L,P＜0.01或P＜0.05].结论 高渗盐水可改善SAP患者的血流动力学状杰并能够抑制全身炎症反应,对SAP的治疗有积极的意义.     

门冬氨酸鸟氨酸对肝切除术后肝功能保护作用的研究

Objective To investigate the protective effects of L-Ornithine-L-Aspartate on liver function in patients after liver resection. Methods Eighty-two patients undergoing liver resection were randomly divided into study group and control group. Control group was treated with conventional therapy and study group had conventional therapy plus L-Ornithine-L-Aspartate for injection intravenously from the first day before operation to the seven day after operation. The fasting alanine aminotransferase (ALT), aspartate aminotransferase ( AST ), γ-glutamyl transpeptadase(GGT), total bilirubin(TB), direct bilirubin(DB) and blood ammonia(BA) levels were determined before operation and on days 1, 3 and 7 after operation. Results On days 1, 3 and 7 after operation, ALT and AST levels in the study group [ALT: ( 115.58 ± 69. 20), (81. 36 ± 14. 55 ), ( 61.24 ± 11. 32) U/L; AST: ( 127.29 ±33.61 ), (95.26 ± 16.83 ), (55.16 ± 14.83 )U/L] were significantly lower than those in the control group[ALT:(175.27 ±68.35), (97.37 ±34.24), (78.28 ± 19. 73) U/L;AST: (152. 29 ±31.65), (115.28 ±35.24),(82.49 ± 28.18) U/L] (P ＜ 0.05 ). In the study group of the porta blocked over 15 min, levels of AST, ALT were obviously lower than that of the control group( P ＜ 0. 05 ). Conclusions L-Ornithine-L-Aspartate for injection can alleviate the hepatic dysfunction after hepatectomy, especially in the long time of porta blocked and has protective advantage for liver function.     

门冬氨酸鸟氨酸对肝切除术后肝功能保护作用的研究

Objective To investigate the protective effects of L-Ornithine-L-Aspartate on liver function in patients after liver resection. Methods Eighty-two patients undergoing liver resection were randomly divided into study group and control group. Control group was treated with conventional therapy and study group had conventional therapy plus L-Ornithine-L-Aspartate for injection intravenously from the first day before operation to the seven day after operation. The fasting alanine aminotransferase (ALT), aspartate aminotransferase ( AST ), γ-glutamyl transpeptadase(GGT), total bilirubin(TB), direct bilirubin(DB) and blood ammonia(BA) levels were determined before operation and on days 1, 3 and 7 after operation. Results On days 1, 3 and 7 after operation, ALT and AST levels in the study group [ALT: ( 115.58 ± 69. 20), (81. 36 ± 14. 55 ), ( 61.24 ± 11. 32) U/L; AST: ( 127.29 ±33.61 ), (95.26 ± 16.83 ), (55.16 ± 14.83 )U/L] were significantly lower than those in the control group[ALT:(175.27 ±68.35), (97.37 ±34.24), (78.28 ± 19. 73) U/L;AST: (152. 29 ±31.65), (115.28 ±35.24),(82.49 ± 28.18) U/L] (P ＜ 0.05 ). In the study group of the porta blocked over 15 min, levels of AST, ALT were obviously lower than that of the control group( P ＜ 0. 05 ). Conclusions L-Ornithine-L-Aspartate for injection can alleviate the hepatic dysfunction after hepatectomy, especially in the long time of porta blocked and has protective advantage for liver function.     

腹腔镜腹腔灌洗引流对重症胰腺炎的临床观察

目的探讨腹腔镜下置管腹腔灌洗引流术（LPLD）对重症急性胰腺炎（SAP）治疗的临床效果及其预后。方法将37例SAP患者按入院先后顺序随机分为内科组和LPLD组。比较两组治疗前后临床症状缓解时间、相关实验室指标及APACHEⅡ评分;并同时统计两组住院时间、住院费用、治愈率和相关并发症。结果两组SAP患者治疗后,LPLD组体温、腹痛等临床症状缓解速度明显快于内科组;LPLD组白细胞、血淀粉酶及APACHEⅡ评分下降显著;与内科组比较,LPLD组住院费用及住院时间明显缩短,两组治愈率无明显差别;两组的腹腔高压持续时间及腹腔感染和脓肿等并发症的发生率差异有统计学意义。结论 LPLD能有效缓解SAP患者临床症状,缩短住院时间及降低住院费用,减少并发症的发生,但是对于该技术的综合评定尚需观察大宗临床病例     

依达拉奉对肝脏缺血再灌注损伤保护作用的临床研究

目的观察依达拉奉对肝切除术患者肝缺血再灌注损伤的保护作用。方法 82例肝切除患者,随机分为对照组(n=40)和试验组(n=42),试验组给予依达拉奉。分别于术前及术后测定中性粒细胞(PMN)计数、血清谷丙转氨酶(ALT)、谷草转氨酶(AST)含量及肝组织中丙二醛(MDA)及超氧化物岐化酶(SOD)活性。结果肝脏缺血再灌注损伤后,对照组的ALT、AST水平及MDA含量明显高于试验组(P0.01或P0.05),SOD活性及PMN计数明显下降(P0.05)。结论依达拉奉对肝脏的缺血再灌注损伤有显著的保护作用,其机制可能与减少PMN在肝脏内的聚集进而调节肝组织氧化与抗氧化平衡有关。     

门冬氨酸鸟氨酸对肝切除术后肝功能保护作用的研究

目的 探讨门冬氨酸鸟氨酸对肝切除患者术后肝功能的保护作用.方法 肝切除患者82例,随机数字法分为对照组40例和研究组42例.对照组给予常规护肝治疗.研究组在对照组治疗措施的基础上,术前1 d应用门冬氨酸鸟氨酸15 g加入5%葡萄糖注射液500 ml静脉滴注,连续用药7 d.分别于术前和术后1、3、7 d晨起空腹测定外周静脉血血清ALT、AST、GGT、胆红素、血氨含量.结果 2组术中肝门阻断的例数及阻断时间差异无统计学意义,同时2组患者肝脏切除方式、切除范围、术中出血量及手术时间差异亦无统计学意义.2组术后肝功能指标与术前相比,有一定程度的升高,差异有统计学意义(均P＜0.05).对照组术后1、3、7 d ALT、AST[ALT分别为(175.27±68.35)、(97.37±34.24)、(78.28±19.73)U/L,AST分别为(152.29 ±31.65)、(115.28±35.24)、(82.49±28.18)U/L]均明显高于研究组[ALT分别为(115.58±69.20)、(81.36±14.55)、(61.24±11.32)U/L,AST分别为(127.29±33.61)、(95.26±16.83)、(55.16±14.83)U/L],差异有统计学意义(均P＜0.05).对照组术后1、3 d的GGT水平明显高于研究组[对照组术后1、3d分别为(325.58±38.19)、(265.68±15.27)U/L,研究组分别为(284.58±19.35)、(204.35±12.35)U/L],差异有统计学意义(P＜0.05).2组术后胆红素水平差异无统计学意义(P＞0.05).肝门阻断＞15 min患者中,研究组患者术后AST、ALT水平明显低于对照组(P＜0.05).结论 门冬氨酸鸟氨酸对肝切除术尤其是肝门阻断时间长的肝损害具有明显保护作用,适合在肝脏围手术期使用.

Abstract：

Objective To investigate the protective effects of L-Ornithine-L-Aspartate on liver function in patients after liver resection. Methods Eighty-two patients undergoing liver resection were randomly divided into study group and control group. Control group was treated with conventional therapy and study group had conventional therapy plus L-Ornithine-L-Aspartate for injection intravenously from the first day before operation to the seven day after operation. The fasting alanine aminotransferase (ALT), aspartate aminotransferase ( AST ), γ-glutamyl transpeptadase(GGT), total bilirubin(TB), direct bilirubin(DB) and blood ammonia(BA) levels were determined before operation and on days 1, 3 and 7 after operation. Results On days 1, 3 and 7 after operation, ALT and AST levels in the study group [ALT: ( 115.58 ± 69. 20), (81. 36 ± 14. 55 ), ( 61.24 ± 11. 32) U/L; AST: ( 127.29 ±33.61 ), (95.26 ± 16.83 ), (55.16 ± 14.83 )U/L] were significantly lower than those in the control group[ALT:(175.27 ±68.35), (97.37 ±34.24), (78.28 ± 19. 73) U/L;AST: (152. 29 ±31.65), (115.28 ±35.24),(82.49 ± 28.18) U/L] (P ＜ 0.05 ). In the study group of the porta blocked over 15 min, levels of AST, ALT were obviously lower than that of the control group( P ＜ 0. 05 ). Conclusions L-Ornithine-L-Aspartate for injection can alleviate the hepatic dysfunction after hepatectomy, especially in the long time of porta blocked and has protective advantage for liver function.     

腹腔镜腹腔灌洗引流对重症胰腺炎的临床观察

目的探讨腹腔镜下置管腹腔灌洗引流术(LPLD)对重症急性胰腺炎(SAP)治疗的临床效果及其预后。方法将37例SAP患者按入院先后顺序随机分为内科组和LPLD组。比较两组治疗前后临床症状缓解时间、相关实验室指标及APACHEⅡ评分;并同时统计两组住院时间、住院费用、治愈率和相关并发症。结果两组SAP患者治疗后,LPLD组体温、腹痛等临床症状缓解速度明显快于内科组;LPLD组白细胞、血淀粉酶及APACHEⅡ评分下降显著;与内科组比较,LPLD组住院费用及住院时间明显缩短,两组治愈率无明显差别;两组的腹腔高压持续时间及腹腔感染和脓肿等并发症的发生率差异有统计学意义。结论 LPLD能有效缓解SAP患者临床症状,缩短住院时间及降低住院费用,减少并发症的发生,但是对于该技术的综合评定尚需观察大宗临床病例。